1. Introduction
Pyrophosphate which has a P-O-P structure is a natural compound found in mammalian cells [1]. Bisphosphonates (BPs) are synthetic analogs of pyrophosphate with a stable P-C-P backbone. BPs have several medicinal applications such as bone targeting, imaging and diagnostic agents, they also present activity against cancer; however, most known is their use as drugs against osteoporosis [2,3]. BPs have a very high affinity for metal cations, which make them very attractive compounds as ligands for metal organic frameworks (MOFs), water purification and metal concentrating agents [4,5,6]. Different kinds of inorganic–organic hybrid materials have been recently used as platforms for studies investigating the controlled release of BPs [7,8,9].
In the literature there are a few methods for the synthesis of 1-hydroxy-1,1-bisphosphonates; Kieczykowsksi et al. reported a method where carboxylic acid was treated with PCl3/H3PO3 in methanesulfonic acid at 65–70 °C followed by hydrolysis with water [10]. Carboxylic acid chlorides or carboxylic acids activated by catecholborane can also be used as a starting material with tris(trimethylsilyl)phosphite [P(OSiMe3)3] at room temperature followed by desilylation with MeOH [11,12]. Maybe the oldest method to synthesize 1-hydroxy-1,1-bisphosphonates concerns preparing tetraesters of BPs followed by acid hydrolysis to obtain the target compounds [13].
2. Results and Discussion
The synthesis method reported by Kieczykowski et al. [10] was first tested to prepare 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid with no success. Our attempts at isolating target BPs by precipitation were unsuccessful. Because of the quite rough conditions of the synthesis method (PCl3 in MeSO3H at 65–70 °C followed by reflux in water -> highly acidic conditions) it was possible, or even likely, that bromine undergoes a substitution reaction (most likely: Br -> OH) and the desired BP becomes impossible to obtain by this method.
6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid mono sodium salt was finally prepared using catecholborane as an activating reagent (see Scheme 1) [11]. 6-bromohexanoic acid was treated with 1 M catecholborane (in THF) followed by the addition of tris(trimethylsilyl) phosphite (2.1 eq), and finally after a bisphosphonation reaction occurred the removal of silyl esters by MeOH. The final compound was precipitated and isolated by the addition of 40% NaOH (1 eq), filtration and re-crystallization from water/EtOH with a 50% yield. A detailed procedure can be found in the Materials and Methods Section.
The target BP was easily characterized by 1H, 13C, 31P NMR spectra. In the 1H NMR spectrum the most characteristic peak was found at 2.01–1.92 ppm (see Supplementary Materials), which is a -CH2- signal next to a P-C-P carbon. In the 13C NMR spectrum the formation of the BP structure was proven by the P-C-P carbon signal at 74.9 ppm, which is in triplet with 1JCP = 136.7 Hz, this is a typical coupling constant and field for 1-hydroxy-1,1-bisphoshonates. In the 31P NMR spectrum only one peak was observed at 19 ppm which is also typical for 1-hydroxy-1,1-bisphoshonates and proved the high purity of the desired BP (no other phosphorus-containing compounds were among the product, such as H3PO4 which can only be observed by 31P NMR spectrum).
3. Materials and Methods
3.1. General
All commercial reagents and solvents were used without further purification. 1H, 31P and 13C NMR spectra were recorded on a 600 MHz Bruker Avance III HD spectrometer equipped with CryoProbe operating at 600.2, 243.0, and 150.9 MHz, respectively. The solvent residual peak (D2O) was used as a standard for 1H measurements, referred to as 4.79 ppm. For the 13C NMR measurements CD3OD was added as a standard, referred to as 49.00 ppm. High-resolution mass spectroscopy (HRMS) was recorded on a q-TOF mass spectrometer (Thermo Scientific, Bremen, Germany) using electrospray ionization (ESI) in the negative mode.
3.2. Synthesis of 6-Bromo-1-hydroxyhexane-1,1-bisphosphonic Acid Monosodium Salt
Synthesis of sodium hydrogen 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid monosodium salt (1). 1 was synthesized by following a previously reported method with some modifications [11]. 1 M catecholborane solution in THF (10.3 mL, 10.3 mmol) was added to a flask containing 6-bromohexanoic acid (2 g, 10.3 mmol) under a nitrogen atmosphere at room temperature. The mixture was stirred for about 1 h until no more gas evolution was observed. Tris(trimethylsilyl) phosphite (6.5 g, 7.3 mL, 21.8 mmol, 2.1 equiv.) was added and stirring was continued for 20 h. Methanol (55 mL) was added and, after stirring overnight, the solvents were evaporated in vacuo. The residue was dissolved in EtOH (20 mL), cooled in an ice-water bath and 1020 µL (1.0 eq) of 40% NaOH was added with stirring. The rection mixture was placed in the freezer overnight and a formed white precipitate was filtered and re-crystallized from water/EtOH (14 mL/20 mL). 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid monosodium salt (1.85 g, 50%) was obtained as a white powder. M.p. 248 °C. 1H NMR (D2O): δ 3.65 (t, 2H, 3JHH = 6.8), 2.01–1.92 (m, 2H), 1.93–1.86 (m, 2H), 1.65–1.57 (m, 2H), 1.49–1.42 (m, 2H). 13C NMR (D2O, CD3OD as ref.) δ 74.9 (t, 1JCP = 136.7, P-C-P), 36.1, 34.4, 32.9, 29.1, 23.2 (t, 2JCP = 6.3). 31P NMR (D2O) δ 19.0. HRMS (ESI-qTOF) m/z: [M − H]− Calcd for C6H14BrO7P2 338.9398; found: 338.9399.
4. Conclusions
The synthesis and characterization of 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid monosodium salt has been reported here for the first time. The 6-bromo group gives possibilities for modifications because it is a rather good leaving group. The reported compound may have potential applications in medicinal and non-medicinal fields.
Not applicable.
Not applicable.
Not applicable.
I would like to thank Marko Lehtonen for MS measurements.
The author declares no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Scheme 1. Synthesis of 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid monosodium salt.
Supplementary Materials
The following are available online. 1H, 13C and 31P NMR spectra of 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid monosodium salt.
References
1. Graham, R.; Russell, G. Bisphosphonates: The first 40 years. Bone; 2011; 49, pp. 2-19.
2. Turhanen, P.A.; Demadis, K.D.; Kafarski, P. Editorial: Phosphonate Chemistry in Drug Design and Development. Front. Chem.; 2021; 9, 695128. [DOI: https://dx.doi.org/10.3389/fchem.2021.695128] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33996774]
3. Turhanen, P.A. Importance of Organophosphorus Compounds in Medicinal Chemistry Field. J. Biomed. Res. Environ. Sci.; 2022; 3, pp. 195-197.
4. Matlinska, M.A.; Ha, M.; Hughton, B.; Oliynyk, A.O.; Iyer, A.K.; Bernard, G.; Lambkin, G.R.; Lawrence, M.C.; Katz, M.J.; Mar, A. et al. Alkaline Earth Metal-Organic Frameworks with Tailorable Ion Release: A Path for Supporting Biomineralization. ACS Appl. Mater. Interfaces; 2019; 11, pp. 32739-32745. [DOI: https://dx.doi.org/10.1021/acsami.9b11004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31414791]
5. Turhanen, P.A.; Vepsäläinen, J.J.; Peräniemi, S. Advanced material and approach for metal ions removal from aqueous solutions. Sci. Rep.; 2015; 5, 8992. [DOI: https://dx.doi.org/10.1038/srep08992] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25758924]
6. Thapa, R.; Rahmani, A.; Turhanen, P.; Taskinen, A.; Nissinen, T.; Neitola, R.; Vepsäläinen, J.; Lehto, V.-P.; Riikonen, J. Recovery of uranium with bisphosphonate modified mesoporous silicon. Sep. Purif. Technol.; 2021; 272, 118913. [DOI: https://dx.doi.org/10.1016/j.seppur.2021.118913]
7. Vassaki, M.; Papathanasiou, K.E.; Hadjicharalambous, C.; Chandrinou, D.; Turhanen, P.; Choquesillo-Lazarte, D.; Demadis, K.D. Self-Sacrificial MOFs for Ultra-Long Controlled Release of Bisphosphonate Anti-Osteoporotic Drugs. Chem. Commun.; 2020; 56, pp. 5166-5169. [DOI: https://dx.doi.org/10.1039/D0CC00439A] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32255461]
8. Vassaki, M.; Kotoula, C.; Turhanen, P.; Choquesillo-Lazarte, D.; Demadis, K.D. Calcium and Strontium Coordination Polymers as Controlled Delivery Systems of the Anti-Osteoporosis Drug Risedronate and the Augmenting Effect of Solubilizers. Appl. Sci.; 2021; 11, 11383. [DOI: https://dx.doi.org/10.3390/app112311383]
9. Vassaki, M.; Lazarou, S.; Turhanen, P.; Choquesillo-Lazarte, D.; Demadis, K.D. Drug-inclusive Inorganic–Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate. Molecules; 2022; 27, 6212. [DOI: https://dx.doi.org/10.3390/molecules27196212] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36234745]
10. Kieczykowski, G.R.; Jobson, R.B.; Melillo, D.G.; Reinhold, D.F.; Grenda, V.J.; Shinkai, I. Preparation of (4-Amino-1-Hydroxybutylidene) bisphosphonic Acid Sodium Salt, MK-217 (Alendronate Sodium). An Improved Procedure for the Preparation of 1-Hydroxy-1,1-bisphosphonic Acids. J. Org. Chem.; 1995; 60, pp. 8310-8312. [DOI: https://dx.doi.org/10.1021/jo00130a036]
11. Egorov, M.; Aoun, S.; Padrines, M.; Redini, F.; Heymann, D.; Lebreton, J.; Mathé-Allainmat, M. A One-Pot Synthesis of 1-Hydroxy-1,1-bis(phosphonic acid)s Starting from the Corresponding Carboxylic Acids. Eur. J. Org. Chem.; 2011; 35, pp. 7148-7154. [DOI: https://dx.doi.org/10.1002/ejoc.201101094]
12. Lecouvey, M.; Mallard, I.; Bailly, T.; Burgada, R.; Leroux, Y. A mild and efficient one-pot synthesis of 1-hydroxymethylene-1,1-bisphosphonic acids. Preparation of new tripod ligands. Tetrahedron Lett.; 2001; 42, pp. 8475-8478. [DOI: https://dx.doi.org/10.1016/S0040-4039(01)01844-5]
13. Nicholson, D.A.; Vaughn, H. A general method of preparation of tetramethyl alkyl-1-hydroxy-1,1-diphosphonates. J. Org. Chem.; 1971; 36, pp. 3843-3845. [DOI: https://dx.doi.org/10.1021/jo00823a621]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
The synthesis of 6-bromo-1-hydroxyhexane-1,1-bisphosphonic acid monosodium salt has been described in detail and characterized by 1H, 13C, 31P NMR spectroscopy and high-resolution MS methods. Bisphosphonates are highly important compounds having a lot of medicinal and non-medicinal applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer